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Abstract
Purpose—To determine the proportional distribution of early- and late-stage breast cancers 
diagnosed in years 2004–2009 among women enrolled in the National Breast and Cervical Cancer 
Early Detection Program (NBCCEDP) and to compare this distribution to that of geographically 
comparable non-enrolled women diagnosed with breast cancer.
Methods—Using data from the National Program of Cancer Registries, we compared the 
demographic characteristics and cancer stage distribution of women enrollees and non-enrollees 
by use of conditional logistic regression using the odds ratio as a measure of association.
Results—NBCCEDP enrollees were slightly younger and more likely to identify as African-
American, API and AIAN than were non-enrollees. The proportion of late-stage breast cancer 
(regional and distant) decreased slightly over the study period. NBCCEDP enrollees generally 
were diagnosed at a later stage of breast cancer than were those not enrolled in the NBCCEDP.
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Conclusions—The NBCCEDP has been effective in achieving its goal of enrolling racial and 
ethnic populations; however, enrollees had a poorer stage distribution of breast cancer than did 
non-enrollees underscoring the need to expand breast cancer control efforts among low-income, 
underserved populations.
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Introduction
Each year more than forty thousand women die of breast cancer and 200,000 are newly 
diagnosed with the disease. Thus, breast cancer remains among the most common cancers 
diagnosed among women in the USA [1]. The American Cancer Society estimates that one 
in eight women in the USA will be diagnosed with the disease sometime in their lifetime [2]. 
The long-term survival of women with breast cancer is dependent on the stage at diagnosis 
and timely treatment after diagnosis. However, disparities in the stage at diagnosis and 
receipt of treatment among subpopulations have been reported in many studies [3–5]. The 
causes of these disparities are complex and are more likely attributable to a combination of 
many factors [3–8]. Among them, one of the most cited factors is socioeconomic status 
(SES) that includes both individual-and area-based SES [6–8]. From these studies, a higher 
prevalence of late stage of breast cancer among women of low SES has been observed.
In 1991, the Centers for Disease Control and Prevention (CDC) created the National Breast 
and Cervical Cancer Early Detection Program (NBCCEDP) for the purpose of increasing 
screening and hence reducing morbidity associated with a diagnosis of breast cancer among 
low-income women [9]. Currently implemented in all 50 states, the District of Columbia, 11 
tribes/tribal organizations, and five territories, the NBCCEDP provides low-income women 
access to breast and cervical cancer screening and diagnostic and treatment services [9]. 
Women are eligible for the NBCCEDP if they are at or below 250 % of the federal poverty 
level, uninsured or underinsured (e.g., have coinsurance costs that are prohibitive), aged 40–
64 years for breast cancer screening, and aged 21–64 years for cervical cancer screening. As 
of October 2013, the NBCCEDP has served more than 4.5 million women, provided more 
than 11 million breast and cervical cancer screening examinations, and has diagnosed more 
than 62,000 breast and over 3,400 cervical cancers [9].
Since the survival benefit of a cancer screening program is related to its ability to detect 
tumors at an earlier stage [10], we examined the proportion of early- and late-stage breast 
tumors diagnosed among NBCCEDP enrollees for diagnosis years 2004–2009 and 
compared these results to non-enrolled women diagnosed with breast cancer who resided in 
the same US census tract at the time of diagnosis. Results from this comparison may assist 
decision makers in determining the needs of NBCCEDP state-funded programs nationwide. 
To our knowledge, this is the first population-based study of a national sample comparing 
NBCCEDP enrollees diagnosed with breast cancer with women diagnosed with breast 
cancer who were not enrolled in the NBCCEDP.
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NPCR is a population-based surveillance system that collects all newly diagnosed cancer 
cases annually through 48 Central Cancer Registries (CCR) in 45 states, the District of 
Columbia, Puerto Rico, and the U.S. Pacific Island Jurisdictions. The system covers 96 % of 
the total US population. To leverage surveillance resources and improve data quality, all 
NPCR programs are required to perform annual data linkages with the NBCCEDP in their 
states to enhance data quality and supplement information in each program's database. 
Patient enrollment status in the NBCCEDP and date of linkage are captured in the NPCR 
database. For this study, we used NPCR breast cancer data from the 2011 annual submission 
and included only those registries that met high data quality and completeness criteria used 
for publication in the USA—United States Cancer Statistics (USCS) [11].
We included women aged 40–64 years with breast as the primary site diagnosed in 2004–
2009. We excluded data from states if: (1) the state-specific linkage rate changed ±10 % 
between sequential diagnostic years, (2) its NBCCEDP caseload accounted for <0.5 % of its 
breast cancer cases, or (3) for any of the diagnosis years, they had missing census tract for 
more than 10 % of their breast cancer cases. Cases identified solely on the basis of the death 
certificate were also excluded from the analysis. Case information was limited to data 
associated with the initial primary diagnosis. Patient's demographic information, stage at 
diagnosis, year at diagnosis, and census tract of residence were collected for all cases [12]. 
Because of complexities in cancer staging collection systems, we based our stage analysis 
on the derived surveillance epidemiology and end results (SEER) Summary Stage 2000 [13]. 
We also examined in situ and local stages together as early stage, while regional and distant 
stages were classified as late stage. The NBCCEDP enrollment status variable was used to 
identify NBCCEDP enrollees.
Women enrolled in NBCCEDP are by definition a very SES disadvantaged group, and 
detailed patient-level SES information was not readily available. Thus, we decided to match 
women enrolled in the NBCCEDP to non-NBCCEDP women in the same census tract of 
residence. We defined census tract strata as a census tract that included at least one breast 
cancer case diagnosed in the NBCCEDP. For these census tracts, we identified women who 
were diagnosed with breast cancer but not linked with the NBCCEDP as our comparison 
subjects. This method of selection excluded 214,306 women with breast cancer who resided 
in census tracts that did not have any NBCCEDP enrollees. We also excluded 336 
NBCCEDP enrollees who resided in census tracts for which no comparison cases were 
available. The final analytic dataset contained 22,858 NBCCEDP enrolled women matched 
with 149,675 non-NBCCEDP women in 13,483 census tracts across 23 states.
For this study, race was classified as White, Black/African-American, American Indian and 
Alaska Native (AIAN), and Asian-Pacific Islander (API). Ethnicity was defined as Hispanic 
and non-Hispanic by the NAACCR Hispanic Identification Algorithm [14]. The category 
Hispanics contains Whites, Blacks, AIAN, and API, but about 80 % of Hispanics are 
classified as Whites. We classified study regions using census region definitions as follows: 
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Northeast (NH, NJ, PA, and RI); Midwest (MO, OH, WI); South (AL, AR, DC, FL, GA, 
KY, LA, NC, OK, and SC); and West (AZ, CA, CO, ID, WA, and WY).
Statistical procedures
We compared women enrolled in the NBCCEDP with non-enrolled women using 
conditional logistic regression. We modeled stage as the outcome variable with NBCCEDP 
enrollment as a predictor variable. We used the odds ratio (OR) as the measure of 
association. We defined the referent category as either local or early-stage breast cancer. We 
evaluated the effect of age, race, and ethnicity on NBCCEDP participation one at a time in 
univariate logistic models as well as included all factors in a multivariable conditional 
logistic regression model to determine the independent contribution of each on NBCCEDP 
enrollment.
We also evaluated putative determinants of stage (age, race, ethnicity, year of diagnosis, and 
region) among the NBCCEDP non-enrollees to identify variables with a significant impact 
on stage at diagnosis. We restricted the analysis to non-enrollees because we wished to 
evaluate the impact of these determinants in the general population in the absence of the 
NBCCEDP effect. Since the NBCCEDP covers only about 1 % of the population, we 
believe that the non-enrollees more adequately represent the general population than do all 
study subjects. We fit logistic models conditional on census tracts with an indicator variable 
for late-stage (distant and regional) breast cancer versus early-stage (in situ and local) breast 
cancer as the outcome variable and included terms for age, race, ethnicity, and year of 
diagnosis. For the analysis pertaining to region of residence at diagnosis, we dropped the 
conditioning on census tracts and used unconditional logistic regression. We could not 
condition on census tracts to estimate the effect of region on stage since matching on census 
tract effectively matches on region.
All analyses were implemented using SAS V9.13 or Stata version 12.
Results
The distribution of breast cancer cases by NBCCEDP enrollment status according to various 
demographic factors is displayed in Table 1. NBCCEDP enrollees are younger than are non-
enrollees (median age and interquartile range of 52 (48, 59) and 53 (48, 59), respectively. 
Compared with Whites in our study population, the odds ratio (OR) of being an enrollee for 
Blacks is 1.7, for AIAN the OR is 1.9, and for API the corresponding OR is 2.2. The odds of 
being enrolled in the NBCCEDP are about fourfold higher among Hispanics compared with 
non-Hispanics. Compared with the Northeast, the OR for residence in the Midwest (OR 1.4) 
and the West (OR 1.4) is increased. However, these ORs are impacted strongly by our 
restrictions in enrollment according to state and our matching on census tracts. The odds of 
inclusion in our study as a NBCCEDP enrollee increased over the study period from 2004 to 
2009. The distribution of all of the factors in Table 1 is statistically significantly different for 
the two NBCCEDP comparative groups (p < 0.0001).
The potential determinants of breast cancer staging are displayed in Table 2. This analysis 
excludes women with missing or unknown races and, as mentioned in the method section, is 
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restricted to non-enrollees in the NBCCEDP. The odds of late-stage breast cancer increased 
monotonically as age at diagnosis decreased. The odds of late-stage breast cancer among 
women aged 40–49 were 22 % higher (p < 0.001) than the odds of late-stage breast cancer 
among women aged 60–64. The odds of late-stage breast cancer were 29 % higher (p < 
0.001) among Blacks compared with Whites and 11 % lower (p < 0.001) among API 
compared with Whites. The odds of late-stage breast cancer did not differ significantly for 
AIAN and Whites. Hispanics had later stage breast cancer than did non-Hispanics (OR 1.12; 
p < 0.001). The prevalence of late-stage breast cancer compared with early-stage breast 
cancer decreased between 2004 and 2009. The odds of late-stage breast cancer were 8 % 
less in 2009 than it was in 2004 (p < 0.001). The decreasing prevalence of late-stage breast 
cancer over time was seen in Whites and API, but not for Blacks (data not shown). 
Compared with Northeast, the odds of late-stage breast cancer are 6 % higher in the 
Midwest (p = 0.01) and 9 % higher in the South (p < 0.001). The odds of late-stage breast 
cancer were not statistically significantly different in Northeast and the West (Table 2).
The comparisons of breast cancer stage between NBCCEDP enrollees and non-enrollees 
according to racial and ethnic categories are displayed in Table 3. For all races combined, 
the odds of in situ breast cancer compared with local-stage breast cancer are significantly 
lower (p < 0.001) among NBCCEDP enrollees compared with non-enrollees. The odds of 
regional-stage and distant-stage breast cancer compared with local-stage breast cancer are 
significantly higher among enrollees compared with non-enrollees (p < 0.001 for both 
regional and distant). This pattern is similar for Whites and API. The differences between 
regional and local breast cancer among Blacks are less pronounced (OR 1.20) than among 
Whites (OR 1.32; p value for effect modification = 0.014). Among Blacks, there is a 
nonsignificant lower odds of distant breast cancer compared with local breast cancer. The 
findings for Hispanics are comparable to the overall findings for all racial–ethnic groups 
combined in that there is a lower odds of in situ compared with local stage. However, for 
Hispanics, there are only slightly higher odds of regional versus local stage, and there are 
significantly lower odds of distant-stage breast cancer compared with local-stage disease.
We repeated these analyses using the late-stage versus early-stage classification of breast 
cancer. For all races combined, the odds ratio for late-stage versus early-stage breast cancer 
for NBCCEDP enrollees compared with non-enrollees was 1.39 (1.35, 1.44). The 
corresponding OR (and 95 % CIs) for Whites was 1.43 (1.38, 1.48); for Blacks 1.26 (1.15, 
1.37); for AIAN 1.69 (0.81, 3.53); and for API 1.38 (1.19, 1.59). The small difference 
between the ORs for Whites and Blacks was statistically significant (p < 0.001), whereas the 
differences in ORs for Whites and AIAN and for Whites and API were not significant (p > 
0.20). For Hispanics, the odds ratio for late-stage versus early-stage breast cancer was 1.08 
(0.99, 1.17) (data not shown).
Discussion
Among women diagnosed with breast cancer, we found that women enrolled in the 
NBCCEDP were slightly younger and more likely to identify as Black or African-American, 
API, or AIAN than the non-enrolled women. We also found that NBCCEDP enrollees were 
more likely to be diagnosed with later stage breast cancer than non-enrolled women. This 
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result was consistent across most racial and ethnic groups except for non-enrolled women 
identified as African-American and Hispanic, who were more often diagnosed at distant 
stage. We believe these observations are generally reflective of NBCCEDP efforts in 
recruiting and serving the rarely or never screened, underserved racial and ethnic 
populations and women with symptoms or clinically worrisome findings. Studies have 
shown that these women generally present with later stage disease [3–5].
Among non-NBCCEDP breast cancer cases, we found that women's age at diagnosis, race, 
ethnicity, and year of diagnosis were all independent determinants of stage at diagnosis after 
controlling for census tract of residence. Region was also related to breast cancer stage in 
that the South had the least favorable stage distribution. However, this finding must be 
interpreted with caution since we excluded many states from the study population because of 
missing census tract information.
Despite recent increases in the incidence of early-stage breast cancer across racial and ethnic 
groups [15], our findings, in accord with previously published studies [16–21], indicate a 
higher burden of late-stage breast cancer among African-American and Hispanic women as 
compared to their White and non-Hispanic counterparts. Interestingly, we found that women 
identified as API are having the highest proportion of early-stage cancer among our study 
population. Future studies should examine correlates between early-stage breast cancer 
among these women and determine whether factors associated with these diagnoses may be 
modified to address the diagnosis of breast cancer among other racial and ethnic groups. 
Nonetheless, undetermined here is whether this increased incidence is an artifact of 
screening practices, improved health-seeking behaviors, or rather a true change in incidence 
among these groups of women. Regardless, the observation that mammogram utilization for 
women aged ≥40 years was highest among African-Americans in the past 10 years [22] is 
paradoxical since the favorable shift is not observed in this analysis. Some studies have 
suggested that tumor characteristics may also contribute to racial disparities in breast cancer 
stage [17, 23, 24] and may be a partial explanation as to why African-Americans have a less 
favorable stage than do Whites and API. Indeed, among all White and African-Americans 
non-NBCCEDP enrollees in our data, the higher odds of regional and distant breast cancer 
compared with local breast cancer for African-Americans compared with Whites is reduced 
by about 25 % after adjustment for tumor grade (data not shown). Nevertheless, the adjusted 
odds of regional and distant breast cancer for African-Americans remain (28 and 77 % for 
regional and distant breast cancer, respectively). Additionally, we observed an inverse 
association between the stage at diagnosis and women's age at diagnosis. This inverse 
association was apparent among the non-NBCCEDP enrollees in our study population. Less 
favorable stage among younger women may indicate more aggressive breast cancer among 
them or could be explainable by higher screening rates among older women.
To our knowledge, this investigation is the first population-based study of a national sample 
to compare breast cancer staging among women in the NBCCEDP to non-enrolled 
NBCCEDP women. There are several possible explanations for the findings we have 
presented. For instance, in the USA, about 9 % of women are eligible for breast cancer 
screening through the NBCCEDP and only about 12 % of the eligible population is actually 
served. Consequently, a large population of women may be unscreened or may experience a 
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delay in enrollment into the NBCCEDP at which point they already are at a more advanced 
stage. For many disadvantaged women, those with symptoms of breast cancer may be 
referred to the NBCCEDP for further work-up and possible treatment, particularly younger 
women as NBCCEDP prioritizes routine screening for women of age 50 and older. If 
women with symptoms or abnormal screening results are preferentially referred to the 
NBCCEDP, they may present with more advanced disease than do women whose 
mammograms are true screening exams. In reducing the incidence of late-stage cancers in 
the NBCCEDP, there is a need for a broader, potentially more universal approach to more 
population-based strategies [25] that reach and educate women on the benefits of routine 
screening prior to symptom onset.
This study has several limitations. The selected areas in our study depended on the 
availability of census tract information from the states, and it may be true that the selected 
areas do not adequately reflect the distribution of stage among all breast cancer cases in the 
NBCCEDP. However, it is unclear how the selection would bias the findings in the direction 
of late-stage disease among NBCCEDP enrollees. We excluded many non-NBCCEDP 
women from our study since we matched our study subjects at the census tract level as an 
attempt to control for SES. Although it may limit generalizability, this exclusion was 
necessary to control indirectly for SES. The fact that the non-enrollees included in our study 
population generally were comparable on demographic factors to those excluded (data not 
shown) indicates little bias from this selection. Although residents of census tracts are 
believed to be relatively homogeneous with respect to economic status and living conditions, 
it may be true that the NBCCEDP enrollees within census tracts are of lower SES than are 
the non-enrollees, and this difference would explain some of the less favorable stage among 
enrollees compared with non-enrollees.
Our findings suggest that there remains a large unmet need for earlier diagnosis of breast 
cancer in the USA, particularly among the low-income and under- or uninsured women. The 
NBCCEDP remains an extremely critical program that helps care for millions of women 
with breast cancer, who otherwise do not have access to care. However, maintained attention 
is warranted as late-stage cancers continue to have a disproportionate impact on specific 
demographic groups in the USA. In addition, as more women gain access to cancer 
screening services through healthcare reform, the NBCCEDP may have the opportunity to 
follow a more population-based approach to extend its reach to areas where gaps persist.
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